US Stock MarketDetailed Quotes
ZURA Zura Bio
- 2.280
- -0.060-2.56%
Close Dec 20 16:00 ET
- 2.280
- 0.0000.00%
Post 16:11 ET
148.87MMarket Cap-3.49P/E (TTM)
2.400High2.160Low1.73MVolume2.310Open2.340Pre Close3.91MTurnover4.23%Turnover RatioLossP/E (Static)65.29MShares6.35052wk High0.97P/B93.18MFloat Cap2.00052wk Low--Dividend TTM40.87MShs Float37.550Historical High--Div YieldTTM10.26%Amplitude2.000Historical Low2.259Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Zura Bio Stock Forum
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...
Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...
SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.1%),Peter Kolchinsky(5.1%), etc.
NEWS
Zura Bio Raises $112.5M Through Private Placement Deal
NEWS
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
No comment yet